Equities Analysts Offer Predictions for GPCR FY2025 Earnings

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) – Investment analysts at Leerink Partnrs dropped their FY2025 EPS estimates for Structure Therapeutics in a report released on Monday, November 10th. Leerink Partnrs analyst D. Risinger now expects that the company will earn ($1.39) per share for the year, down from their prior estimate of $1.50. The consensus estimate for Structure Therapeutics’ current full-year earnings is ($0.82) per share. Leerink Partnrs also issued estimates for Structure Therapeutics’ Q4 2025 earnings at ($0.39) EPS, FY2026 earnings at $1.08 EPS, FY2028 earnings at ($1.81) EPS and FY2029 earnings at $0.78 EPS.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.01).

Several other brokerages also recently weighed in on GPCR. HC Wainwright cut their price target on Structure Therapeutics from $75.00 to $60.00 and set a “buy” rating on the stock in a report on Thursday, August 7th. Zacks Research cut shares of Structure Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Friday, October 17th. Lifesci Capital raised Structure Therapeutics to a “strong-buy” rating in a report on Monday, September 8th. Piper Sandler restated an “overweight” rating on shares of Structure Therapeutics in a research report on Tuesday, October 28th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Structure Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $68.67.

Structure Therapeutics Price Performance

NASDAQ GPCR traded down $0.22 during trading hours on Thursday, hitting $35.71. 86,084 shares of the company’s stock traded hands, compared to its average volume of 908,484. The firm’s 50-day moving average is $27.24 and its 200-day moving average is $23.20. The company has a market capitalization of $2.06 billion, a PE ratio of -29.36 and a beta of -1.63. Structure Therapeutics has a 52-week low of $13.22 and a 52-week high of $38.48.

Institutional Trading of Structure Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. EverSource Wealth Advisors LLC boosted its holdings in Structure Therapeutics by 530.0% in the third quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock worth $30,000 after acquiring an additional 901 shares in the last quarter. State of Wyoming bought a new stake in Structure Therapeutics in the 2nd quarter worth about $28,000. Assetmark Inc. boosted its holdings in shares of Structure Therapeutics by 39.9% in the 2nd quarter. Assetmark Inc. now owns 2,877 shares of the company’s stock worth $60,000 after buying an additional 820 shares during the last quarter. National Bank of Canada FI raised its stake in Structure Therapeutics by 1,448.2% in the 1st quarter. National Bank of Canada FI now owns 2,957 shares of the company’s stock valued at $51,000 after acquiring an additional 2,766 shares during the period. Finally, ANTIPODES PARTNERS Ltd lifted its position in shares of Structure Therapeutics by 39.1% during the third quarter. ANTIPODES PARTNERS Ltd now owns 4,078 shares of the company’s stock worth $114,000 after acquiring an additional 1,146 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.